A) Overall survival (OS) and (B) progression-free survival (PFS).... | Download Scientific Diagram
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Diagnostics | Free Full-Text | Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan-Meier curve of median progression-free survival (PFS) and... | Download Scientific Diagram
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
